First European implants of Ramon pulmonary artery pressure monitor
18 October 2006. Deutsch
Caesarea, Israel. The first set of patients in Europe have received
implants of the Remon ImPressure haemodynamic monitor from Remon Medical
Technologies, Inc. The medical device offers on-demand, non-invasive,
wireless self-monitoring of pulmonary artery pressure by the patient at
ImPressure devices were implanted in four patients, at two sites in
Germany. In all four cases, pulmonary artery pressure readings were
successfully transmitted to the hand-held home monitor and the clinic unit
immediately after the implantation and in subsequent follow-ups.
Professor Dr. Uta Hoppe, of the Internal Medicine Department, University
of Cologne noted that "After implanting the Remon ImPressure, the hand-held
home unit provides the patient with a unique tool for self monitoring. This
monitor will be easy for my patients to use at home, and is expected to give
early warning of the need for treatment, avoiding hospitalization and
deterioration in the patient's condition."
Data from the hand-held monitor can be downloaded to a laptop clinic
system, displaying a history of the patient's pulmonary pressure readings.
"This graphic display of pulmonary artery pressure waveform will certainly
assist in determining optimal treatment for each patient, resulting in
better disease management," added Professor Hoppe.
The Remon ImPressure is introduced percutaneously, via a simple vein
catheterization procedure, using jugular or femoral access. The miniature
device, based on Remon's proprietary acoustic technology, is wireless and
leadless. The patient uses a portable battery-operated hand-held unit to
interrogate the implant. The measurement can be taken at home, or away from
home, without any special preparation, and without exposing the patient to
Professor Dr. Horst Sievert, Director of the CardioVascular Centre
Frankfurt, Sankt Katharinien, commented: "I was impressed by the simplicity
and ease of delivering the ImPressure to the pulmonary artery. The
physician's ability to choose between intra-jugular and femoral approaches
and the low profile of the delivery system add significantly to the system
Hezi Himelfarb, Remon's CEO, said: "We are excited to see our device
implanted for the first time in Europe, as part of a trial to meet the
requirements for CE mark regulatory approval. Our device demonstrates the
inherent value of Remon's unique acoustic communication. We believe that our
technology has many other applications that will dramatically impact several
areas within medicine".